Taiwan Liposome Company (TLC)
2F, 3 Yuanqu Street
Nankang
Taipei
115
Tel: 886-2-2655-7377
Fax: 886-2-2655-7366
Website: http://www.tlcbio.com/
Email: info@tlcbio.com
About Taiwan Liposome Company (TLC)
Taiwan Liposome Company (TLC) is a biopharmaceutical company focused on the research, development and commercialization of innovative pharmaceutical products based on its proprietary drug delivery technologies. Our strengths lie in lipid-based formulation and scale-up for parenteral drugs using micelles and nanoparticles to optimize the pharmacokinetics of drugs for better efficacy and lower toxicity, and thus prolong the product lifecycle of branded drugs.YEAR FOUNDED:
1997
LEADERSHIP:
Founder and CEO: Keelung Hong
CFO: Nicole Lin
JOBS:
Please click here for TLC job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
FOLLOW TLC:
Tweets by TLC
69 articles about Taiwan Liposome Company (TLC)
-
TLC to Present at HC Wainwright & Co. 22nd Annual Global Investment Conference
9/9/2020
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that the Company’s President Mr. George Yeh and Chief Medical Officer Dr. George Spencer-Green, MD, will be presenting at HC Wainwright & Co’s 22nd Annual Global Investment Conference on Monday, September 14, 2020, at 10:00am ET.
-
TLC to Present at Baird’s 2020 Global Healthcare Conference
9/3/2020
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that George Yeh, President of TLC, will be presenting the latest updates on the company in a fireside chat with Madhu Kumar, Senior Research Analyst, at Baird’s 2020 Global Healthcare Conference on Wednesday, September 9, 2020 at 8:30am ET.
-
TLC and 3SBio Announce Acceptance of Marketing Authorization Application for Ampholipad™ in China
8/26/2020
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, in conjunction with 3SBio, announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted its Marketing Authorization Application for Ampholipad™, TLC’s complex generic of Gilead’s AmBisome® used for the treatment of systemic fungal infections.
-
TLC Submits Investigational New Drug (IND) Application for TLC19 Inhalable Liposomal Hydroxychloroquine for COVID-19
8/14/2020
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced the submission of an Investigational New Drug Application to the Taiwan Food and Drug Administration for TLC19 Hydroxychloroquine Liposome Inhalation Suspension for the treatment of coronavirus disease 2019.
-
TLC Reports Second Quarter 2020 Financial Results and Provides Business Update
8/5/2020
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced financial results for the second quarter ending June 30, 2020, and provided a business update.
-
Manuscript Describes How TLC’s Inhalable Liposomal Hydroxychloroquine May Provide Clinical Benefit and Serve as Potential Treatment for COVID-19
7/15/2020
Achieving 30x exposure in lungs at significantly lower dose while reducing systemic and cardiac toxicities
-
TLC Announces Completion of US$23 Million Financing
6/30/2020
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, is pleased to announce that it has closed its 2020 cash capital offering of ordinary shares in Taiwan, with the record date of June 30, 2020.
-
TLC Announces Topline Results for TLC590 Phase II Trial for Postsurgical Pain Management following Bunionectomy
5/31/2020
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, announced topline results from the TLC590 Phase II clinical trial, a randomized, double-blind, placebo- and comparator- controlled study of TLC590 in patients following bunionectomy.
-
TLC Highlights Findings in Abstract Accepted at Osteoarthritis Research Society International (OARSI) 2020 and Published in Osteoarthritis and Cartilage
5/18/2020
TLC Highlights Findings in Abstract Accepted at Osteoarthritis Research Society International (OARSI) 2020 and Published in Osteoarthritis and Cartilage
-
TLC Reports First Quarter 2020 Financial Results and Provides Business Update
5/13/2020
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, announced financial results for the first quarter ending March 31, 2020, and provided a business update.
-
TLC Earns Highest Ranking in Corporate Governance Evaluation Six Years in a RowTLC is the only listed biotech company to achieve the elite status every year
5/4/2020
TLC announced that it has been ranked in the Top 5% in Corporate Governance Evaluation amongst all Taiwan Stock Exchange Corporation and Taipei Exchange listed companies in the sixth annual evaluation, becoming the only biotech company to have received this status for six consecutive years.
-
TLC Announces Early Completion of Patient Enrollment in TLC590 Phase II Clinical Trial following Bunionectomy
2/12/2020
Topline results on the analgesic efficacy of TLC590 for postsurgical pain management following the hard tissue surgery are expected in mid-2020
-
TLC Reports Fiscal Year End 2019 Financial Results and Provides Business Update
2/11/2020
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, announced financial results for the fiscal year ended December 31, 2019, and provided a business update.
-
TLC Announces Dosing of First Patients in Part 2 of TLC590 Phase II Trial for Postsurgical Pain following Bunionectomy
1/8/2020
TLC announced that the first batch of patients has been dosed in Part 2 of the Phase II clinical trial for TLC590 in patients following bunionectomy surgery.
-
TLC to Present at 38th Annual JP Morgan Healthcare Conference
1/2/2020
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, has been invited to present at the 38th annual JP Morgan Healthcare Conference, which takes place in San Francisco January 13-16, 2020.
-
TLC to Hold Investor Conference in Taipei
11/29/2019
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, has been invited by MasterLink Securities to hold an investor conference on December 6, 2019.
-
TLC Announces Completion of US$27 Million Financing
10/24/2019
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, is pleased to announce that it has closed its 2019 cash capital offering of ordinary or common shares in Taiwan.
-
TLC Reports Third Quarter 2019 Financial Results and Provides Business Update
10/22/2019
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, announced financial results for the third quarter ended September 30, 2019, and provided a business update.
-
TLC Presents Clinical and Preclinical Data of TLC590 at ANESTHESIOLOGY® Annual Meeting and in International Journal of Nanomedicine TLC590 showed faster and longer lasting pain relief than ropivacaine
10/21/2019
TLC recently presented data at the American Society of Anesthesiologists ANESTHESIOLOGY® annual meeting from a Phase I/II clinical trial which showed TLC590 to yield more immediate and long-lasting pain reduction than ropivacaine.
-
TLC Appoints Vincent Chang, PhD, as Vice President of Manufacturing Development
10/20/2019
TLC, a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in pain management, ophthalmology and oncology, announced the appointment of Vincent Chang, PhD, as TLC’s Vice President of Manufacturing Development.